# STC-15 is the world’s first RNA-modifying enzyme inhibitor to reach human trials.

*biotech · news · 2026-04-16 · TNW*

## Key points

- STC-15 is the world’s first RNA-modifying enzyme inhibitor to reach human clinical trials.
- In Phase 1, STC-15 showed durable tumour regression across multiple sarcoma subtypes and dose levels.
- STORM Therapeutics raised $56 million in Series C funding entirely from existing investors, including Pfizer Ventures.
- A Phase 2 monotherapy trial of STC-15 has dosed its first patient and aims for accelerated regulatory approval.
- STC-15 is also being tested in combination with toripalimab across multiple other cancer types.

**Companies:** Pfizer Ventures, STORM Therapeutics, Coherus BioSciences
**Countries:** United States, United Kingdom, Japan

[Read the full story on TNW](https://thenextweb.com/news/storm-therapeutics-56m-series-c)

---

Canonical: https://newsio.io/n/1c17b356-d045-4021-9c1e-22b0dc075cba/stc-15-is-the-worlds-first-rna-modifying-enzyme-inhibitor-to-reach-human-trials
Summarized by Newsio from TNW. https://newsio.io/how-it-works